<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556696</url>
  </required_header>
  <id_info>
    <org_study_id>2016_48</org_study_id>
    <secondary_id>2017-A00858-45</secondary_id>
    <nct_id>NCT03556696</nct_id>
  </id_info>
  <brief_title>Automatic Remifentanil Administration Guided by ANI During Propofol Anesthesia</brief_title>
  <acronym>ANI-LOOP</acronym>
  <official_title>Automatic Remifentanil Administration Guided by the Analgesia Nociception Index During Propofol Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Randomized Monocentric Clinical Trial during propofol anesthesia. The aim of the
      study is to test whether the use of a medical device designed to automatically administer
      remifentanil during surgery based on expert rules and continuous reading of heart rate, blood
      pressure and the Analgesia Nociception Index results in lower overall remifentanil
      administration versus standard practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective Randomized Monocentric Clinical Trial during propofol anesthesia.

        -  inclusion: ASA 1, 2 or 3 adult patients scheduled to undergo burn wound surgery in a
           Burn Center (University Hospital of Lille, France)

        -  arm 1 : Remifentanil will be automatically administered by an expert system guided by
           heart rate, blood pressure and the Analgesia Nociception Index (ANI).

        -  arm 2 : Remifentanil will be administered by a target controlled device using the Minto
           pK/pD model.

        -  propofol is administered throughout the procedure with a target controlled device using
           the pK/pD model of Schnider. The target will be guided by the BiSpectral index values.

        -  primary endpoint : overall normalized remifentanil administration.

        -  secondary endpoints : relative amount of time spent in a state of hemodynamic reactivity
           ; relative amount of time the ANI spends in the [0-50], [50-70] and [70-100] windows ;
           relative amount of time the BIS spends in the [0-40], [40-60] and [60-100] ; hemodynamic
           status at various times during anesthesia ; total amount of target modifications of
           remifentanil and propofol ; total amount of morphine administered in PACU ; total amount
           of ketamine administered in PACU ; incidence of nausea/vomiting in PACU ;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Monocentric prospective randomized controlled clinical trial
arm 1: medical device automatically administering remifentanil, guided by expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)
arm 2 : standard practice : remifentanil is administered using a target controlled device using a pK/pD model of Minto</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>normalized remifentanil administration</measure>
    <time_frame>During the surgery, an average Three hours and a half</time_frame>
    <description>ratio of total amount of administered remifentanil with body weight and duration of administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemodynamic reactivity or bradycardia or hypotension</measure>
    <time_frame>During the surgery, an average Three hours and a half</time_frame>
    <description>relative amount of time during which heart rate or SBP exceed 120% of baseline, or heart rate drops below 40/min, or SBP drops below 75 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total administered ephedrine</measure>
    <time_frame>duration of general anesthesia</time_frame>
    <description>total amount of ephedrine administered during general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia Nociception Index (ANI)</measure>
    <time_frame>During the surgery, an average Three hours and a half</time_frame>
    <description>relative amount of time spent with ANIi in the [0-50], [50-70] and [70-100] windows. Same with ANIm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral Index (BIS)</measure>
    <time_frame>During the surgery, an average Three hours and a half</time_frame>
    <description>relative amount of time spent with BIS in the [0-40], [40-60] and [60-100] windows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change antinociception/nociception balance status</measure>
    <time_frame>5 min before start of nociception, 5 min after start of nociception and 20 min after start of nociception</time_frame>
    <description>composite measure: heart rate, blood pressure, ANIi, ANIm, end-tidal CO2, PeakPressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain in PACU</measure>
    <time_frame>During the first two postoperative hours</time_frame>
    <description>Visual Analog Scale every 15 min in PACU The pain VAS is a continuous scale comprised of a horizontal (HVAS) or vertical (VVAS) line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme (0, 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morphine in PACU</measure>
    <time_frame>During the first two postoperative hours</time_frame>
    <description>Total amount of administered morphine during PACU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ketamine in PACU</measure>
    <time_frame>During the first two postoperative hours</time_frame>
    <description>Total amount of administered ketamine during PACU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea/vomiting in PACU</measure>
    <time_frame>During the first two postoperative hours</time_frame>
    <description>reported number of nausea/vomiting during PACU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remi target changes</measure>
    <time_frame>During the surgery, an average Three hours and a half</time_frame>
    <description>total number of target changes during general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>propofol target changes</measure>
    <time_frame>During the surgery, an average Three hours and a half</time_frame>
    <description>total number of target changes during general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>normalized propofol administration</measure>
    <time_frame>During the surgery, an average Three hours and a half</time_frame>
    <description>ratio of total amount of propofol administered with body weight and duration of general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANI-REMI-loop switch to manual</measure>
    <time_frame>During the surgery, an average Three hours and a half</time_frame>
    <description>number of interventions on ANI-REMI-loop device: switch to manual</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Nociceptive Pain</condition>
  <condition>Surgical Procedure, Unspecified</condition>
  <arm_group>
    <arm_group_label>ANI-loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>arm 1 : remifentanil is automatically administered by a medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>std_practice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>arm 2: remifentanil is administered by a target control device using Minto's remifentanil pK/pD model. This is standard practice for this type of surgery at the Burn Center of the University Hospital of Lille, France.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ANI-REMI-loop</intervention_name>
    <description>experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration</description>
    <arm_group_label>ANI-loop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>remifentanil pK/pD target administration device</intervention_name>
    <description>standard practice, remifentanil administration using Minto's pK/pD model</description>
    <arm_group_label>std_practice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the [50-70] range.</description>
    <arm_group_label>ANI-loop</arm_group_label>
    <arm_group_label>std_practice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in [40-60] range</description>
    <arm_group_label>ANI-loop</arm_group_label>
    <arm_group_label>std_practice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ANI monitor</intervention_name>
    <description>ANI (Analgesia Nociception Index) value is used in the &quot;std_practice&quot; arm for guidance of the remifentanil Ce target</description>
    <arm_group_label>std_practice</arm_group_label>
    <other_name>PhysioDoloris (MDMS, Loos, France)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA 1, 2 or 3 adult patients scheduled to undergo burn wound surgery at the Burn
             Center of the University Hospital of Lille

        Exclusion Criteria:

          -  BMI outside [17 - 35 kg/m2]

          -  pregnancy or breast feeding women

          -  non sinus cardiac rhythm

          -  documented dysautonomia

          -  complicated diabetes mellitus

          -  known allergy to a drug used in the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu JEANNE, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu JEANNE, MD,PhD</last_name>
    <phone>3 20 44 40 74</phone>
    <phone_ext>+33</phone_ext>
    <email>mathieu.jeanne@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital Roger Salengro, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mathieu Jeanne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>general anesthesia</keyword>
  <keyword>analgesia/nociception balance monitoring</keyword>
  <keyword>expert system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

